TY - JOUR A1 - Pfeiffer, Anett A1 - Thalheimer, Frederic Bastian A1 - Hartmann, Sylvia A1 - Frank, Annika A1 - Bender, Ruben Raphael A1 - Danisch, Simon A1 - Costa, Caroline A1 - Wels, Winfried A1 - Modlich, Ute A1 - Stripecke, Renata A1 - Verhoeyen, Els A1 - Buchholz, Christian T1 - In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome T2 - EMBO molecular medicine N2 - Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell malignancies. Notwithstanding, CAR T‐cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19‐CAR T cells can be generated directly in vivo using the lentiviral vector CD8‐LV specifically targeting human CD8+ cells. Administration into mice xenografted with Raji lymphoma cells and human peripheral blood mononuclear cells led to CAR expression solely in CD8+ T cells and efficacious elimination of CD19+ B cells. Further, upon injection of CD8‐LV into mice transplanted with human CD34+ cells, induction of CAR T cells and CD19+ B‐cell depletion was observed in 7 out of 10 treated animals. Notably, three mice showed elevated levels of human cytokines in plasma. Tissue‐invading CAR T cells and complete elimination of the B‐lymphocyte‐rich zones in spleen were indicative of a cytokine release syndrome. Our data demonstrate the feasibility of in vivo reprogramming of human CD8+ CAR T cells active against CD19+ cells, yet with similar adverse effects currently notorious in the clinical practice. KW - cytokine release syndrome KW - gene delivery KW - humanized mouse KW - T-cell targeting Y1 - 2018 UR - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/47384 UR - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-473846 SN - 1757-4684 SN - 1715-4684 SN - 1757-4676 N1 - © 2018 The Authors. Published under the terms of the CC BY 4.0 license VL - 10 IS - e9158 SP - 1 EP - 11 PB - Wiley-VCH ; EMBO Press CY - Weinheim ; Heidelberg ER -